



OUR IMMUNOTHERAPY PRODUCTS ARE WELL POSITIONED IN RAPIDLY GROWING MARKETS WITH HIGH MEDICAL NEEDS.

About

NantKwest (Nasdaq: NK), is a pioneering, next generation, clinical-stage Immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body's first line of defense due to the innate ability of NK cells to rapidly identify and destroy cells under stress, such as cancer or virally-infected cells.

NantKwest's unique NK cell based platform, with the capacity to grow active killer cells as a biological cancer therapy, has been designed to induce cell death against cancer or infected cells by three different modes of action:

- (1) Direct killing using activated NK cells (aNK) that release toxic granules directly into the cell through cell to cell contact,
- (2) Antibody-mediated killing using haNKs, which are NK cells engineered to incorporate a high affinity receptor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody, and
- (3) Target-activated killing using the taNK™ platform, which includes NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells

Our aNK, haNK® and taNK™ platform addresses certain limitations of T-cell therapies including the reduction of risk of serious "cytokine storms." As an "off-the-shelf" therapy, NantKwest's NK cells do not rely on a patient's own often compromised immune system. In Phase 1 clinical trials in patients with late stage cancer, NantKwest's NK cells has been successfully administered as an outpatient infusion therapy without any reported severe side effects, even at doses of 10 billion cells.

By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs that include a phase 2 trial for a rare form of melanoma and the planned initiation of a clinical trial of NK cells targeted to breast cancer, we believe NantKwest is uniquely positioned to be the premier immunotherapy company and transform medicine by delivering living drugs in a bag and bringing novel NK cell-based therapies to routine clinical care.

[Learn more about our technology](#)

HARNESSING THE NATURAL ORDER OF OUR IMMUNE SYSTEM

Living Drugs in a Bag® therapy
OUR WAR AGAINST CANCER


Technology

OVERVIEW - A Next Generation Immunotherapy Platform

The Natural Killer Cell


The immune system is a tapestry of diverse families of immune cells each with its own distinct role in protecting from infections and diseases. Among these immune cells are the natural killer, or NK, cells as the body's first line of defense. **NK cells have the innate ability to rapidly seek and destroy abnormal cells, such as cancer or virally infected cells, without prior exposure or activation by other support molecules.** In contrast to adaptive immune cells such as T-cells, NK cells are uniquely powerful in that they are always activated to attack diseased cells, without a delay in killing. Our proprietary activated Natural Killer (aNK) platform is based upon highly potent Natural Killer cells from a unique cell line, harnessing the power of the innate immune system.

FULL POWER OF OUR BODY'S OWN IMMUNE SYSTEM



We're harnessing the full power of our body's own immune system, by developing treatments which utilize natural killer cells, our body's first line of defense in the battle against cancer!

We've discovered a unique variant of natural killer cells called aNK that lacks inhibitory receptors but has a broad array of activating receptors



DISCOVERED A UNIQUE NATURAL KILLER CELL

aNK


UNIVERSAL CELL-BASED THERAPY

DOESN'T require individualized patient matching

MANUFACTURED AT SCALE

OFF-THE-SHELF APPROACH

Can be administered in an outpatient setting



Living Drugs in a Bag® Therapy

OUTPATIENT SETTING

One Mission - Three NK Platforms

NantKwest's unique NK cell based platform, with the capacity to grow active killer cells as a biological cancer therapy, has been designed to induce cell death against cancer or infected cells by three different modes of action:

UNIQUE PLATFORM - MULTIPLE APPROACHES TO TARGETED KILLING



aNK



haNK



taNK

aNK: Activated Natural Killer

Direct killing using NK-92 derived activated NK cells (aNK) that release toxic granules directly into the cancer cells through cell-to-cell contact.

haNK®

Antibody-mediated killing using haNKs, which are aNK cells engineered to incorporate a high affinity receptor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody.

taNK®

Target-activated killing using taNKs, which are NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells.

